Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)
Hypertension

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
Part I:
- Is a male between 18 to 50 years of age
- Is in good health
- Is a non-smoker
Part II:
- Is male of non-child bearing potential between 18 and 50 years of age
- Has hypertension (high blood pressure)
Exclusion Criteria:
Part I and Part II:
- Has a history of stroke, seizures or major neurological disorder
- Has a history of cancer
- Has a history of any cardiovascular disease
- Is unable to refrain from the use of any prescription or non-prescription drugs
- Consumes excessive amounts of alcohol or caffeine
- Has had major surgery, donated blood or participated in another investigational study in the past 4 weeks
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Pbo → 5 mg → Candesartan → 24 mg → 38 mg
1 mg → 5 mg → 12 mg → Candesartan → Pbo
1 mg → Candesartan → Pbo → 24 mg → 38 mg
1 mg → 5 mg → 12 mg → Pbo → Candesartan
Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan
2 mg→Pbo → Candesartan → Pbo fed→38 mg
2 mg→Candesartan→Pbo→Candesartan fed→38 mg
2 mg → 8 mg → 18 mg → 2 mg fed → Pbo
Candesartan→8 mg→ 18 mg →2 mg fed→38 mg
Candesartan→Pbo → 12 mg → 24 mg→38 mg
Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.